Jesus Avila | Tauopathies | Best Researcher Award

Published on by Cognitive Scientist Awards

Prof. Jesus Avila | Tauopathies | Best Researcher Award

Dr. Jesus Avila is a distinguished cognitive scientist and Professor ad honorem at the Centro de Biologia Molecular Severo Ochoa (CBM-CSIC), Spain. He obtained his degree in Chemistry and PhD in Molecular Biology from Universidad Complutense Madrid, focusing on RNA polymerase in B. subtilis. His postdoctoral research at NIH, USA, centered on the SV40 virus. Throughout his prolific career, Dr. Avila has made groundbreaking contributions to understanding the neuronal cytoskeleton, particularly tau protein, its role in Alzheimer’s disease, and tauopathies. With over 694 published journal articles, 33 books, 4 patents, and collaborations across the USA, France, UK, Germany, and Spain, his work is internationally recognized. He serves on editorial boards of prestigious journals including EMBO J, FEBS Letters, Neuroscience, and Journal of Alzheimer’s Disease (Deputy Editor). Dr. Avila is a member of EMBO, Academia Europaea, AAAS, and Royal Academies of Sciences and Medicine of Spain.

Professional Profile

Education

Dr. Jesus Avila pursued his higher education at Universidad Complutense Madrid (UCM), earning a degree in Chemistry. He further specialized by completing a PhD in Molecular Biology at UCM, where his research focused on the B. subtilis RNA polymerase system. This solid foundation in molecular biology provided him with the expertise to investigate complex neurobiological mechanisms. He then advanced his academic career with postdoctoral training at the National Institutes of Health (NIH) in Bethesda, Maryland, USA, where he studied the SV40 virus—a crucial step that introduced him to advanced molecular virology and neurobiology techniques. This diverse academic background enabled him to establish a globally recognized research portfolio in neurodegeneration, particularly tau protein’s role in neuronal function and dysfunction.

Experience

Dr. Avila has an illustrious career spanning several decades at the Centro de Biologia Molecular Severo Ochoa (CBM-CSIC), where he has led pioneering research into the neuronal cytoskeleton, tau protein dysfunction, and neurodegenerative diseases. His early research at NIH on SV40 virus provided him with robust molecular expertise, which he translated into comprehensive studies on tauopathies and Alzheimer’s disease upon returning to Spain. Dr. Avila has successfully led over 30 major research projects, consulted on 8 industry collaborations, and published 694 peer-reviewed articles. His work includes the authorship of 33 books and the filing of 4 patents. Through sustained collaborations with global leaders in neuroscience from the USA, France, UK, Germany, and Spain, he has significantly advanced the understanding of aging and cognitive decline. His academic leadership and editorial roles underscore his vast experience in guiding both research and scientific discourse.

Research Interests

Dr. Avila’s research primarily investigates the neuronal cytoskeleton, with a central focus on tau protein and its role in neurodegeneration. Beginning with tau’s structural function in neurons, his work has expanded to explore how tau dysfunction contributes to Alzheimer’s disease and other tauopathies. Utilizing molecular and cellular approaches, including advanced mouse models, he has dissected the pathological mechanisms linking tau pathology to cognitive decline. Recognizing aging as the principal risk factor for Alzheimer’s disease, his current investigations target neuronal rejuvenation strategies to mitigate age-associated neurodegeneration. His integrative approach combines molecular biology, neurogenetics, and translational models, contributing significantly to the understanding of disease progression and potential therapeutic interventions. Through over 694 publications, 33 books, multiple patents, and international collaborations, Dr. Avila has substantially advanced the field of cognitive neuroscience, particularly in understanding and combating tau-mediated cognitive disorders.

Awards

Dr. Avila’s exemplary contributions have earned him numerous prestigious honors. He is an elected member of EMBO (European Molecular Biology Organization), Academia Europaea, AAAS (American Association for the Advancement of Science), and both the Royal Academies of Sciences and Medicine of Spain—testament to his global recognition and scientific excellence. His editorial appointments with highly respected journals such as EMBO J, FEBS Letters, Neuroscience, and his role as Deputy Editor of the Journal of Alzheimer’s Disease further validate his authority in cognitive and neurodegenerative research. His citation index surpasses 100 on Scopus, reflecting the significant influence of his work. His extensive collaborations with leading international research teams highlight his status as a respected leader in the global scientific community. The combination of his research excellence, mentorship, and leadership has positioned him as one of the foremost experts in cognitive science and neurobiology.

Conclusion

Dr. Jesus Avila’s distinguished career combines pioneering research on tau protein and Alzheimer’s disease, extensive international collaborations, over 694 publications, leadership roles in major journals, multiple prestigious memberships, and an unwavering focus on neuronal rejuvenation strategies, positioning him as a world-leading cognitive scientist whose work continues to advance global understanding of neurodegeneration.

 Publications

  • Protein tau phosphorylation in the proline rich region and its implication in the progression of Alzheimer’s disease

    Experimental Neurology
    2025 | Journal article
    DOI: 10.1016/j.expneurol.2024.115049

    EID:

    2-s2.0-85208758184

    Part ofISSN: 10902430 00144886
    CONTRIBUTORS: Merino-Serrais, P.; Soria, J.M.; Arrabal, C.A.; Ortigado-López, A.; Esparza, M.Á.G.; Muñoz, A.; Hernández, F.; Ávila, J.; DeFelipe, J.; León-Espinosa, G.

  • Retrotransposon Protein L1 ORF1p Expression in Aging Central Nervous System

    International Journal of Molecular Sciences
    2025-05-04 | Journal article
    DOI: 10.3390/ijms26094368
    CONTRIBUTORS: Laura Vallés-Saiz; Aaron Abdelkader-Guillén; Jesús Ávila; Félix Hernández

  • Shapeshifter W-Tau Peptide Inhibits Tau Aggregation and Disintegrates Paired Helical Filaments

    Biochemistry
    2025-04-15 | Journal article
    DOI: 10.1021/acs.biochem.4c00809
    CONTRIBUTORS: Indalo Domene-Serrano; Raquel Cuadros; Vega García-Escudero; Francisco Vallejo-Bedia; Ismael Santa-María; Laura Vallés-Saiz; Félix Hernandez; Jesús Avila

  • Peptide Family Promotes Brain Cell Rejuvenation and Improved Cognition through Peripheral Delivery

    ACS Omega
    2025-04-08 | Journal article
    DOI: 10.1021/acsomega.4c10849
    CONTRIBUTORS: Alejandro Anton-Fernandez; Indalo Domene-Serrano; Raquel Cuadros; Rocio Peinado-Cahuchola; Margarita Sanchez-Pece; Felix Hernandez; Jesus Avila

  • Partial reprogramming by cyclical overexpression of Yamanaka factors improves pathological phenotypes of tauopathy mouse model of human Alzheimer\’s disease

    Progress In Neurobiology
    2025-04-01 | Journal article | Author
    DOI: 10.1016/j.pneurobio.2025.102743

    SOURCE-WORK-ID:

    CSIC-GB950859

    EID:

    2-s2.0-85219079150

    Part ofISSN: 0301-0082
    CONTRIBUTORS: Alejandro Anton-Fernandez; Ruiz de Alegría, Álvaro; Mariscal-Casero, Ana; Roldán-Lázaro, Marta; Peinado-Cauchola, Rocío; Jesus Avila; Felix Hernandez

  • Hippocampal rejuvenation by a single intracerebral injection of one‐carbon metabolites in C57BL6 old wild‐type mice

    Aging Cell
    2025-01 | Journal article
    DOI: 10.1111/acel.14365
    CONTRIBUTORS: Alejandro Antón‐Fernández; Rocío Peinado Cauchola; Félix Hernández; Jesús Ávila

  • Intron retention as a productive mechanism in human MAPT: RNA species generated by retention of intron 3

    eBioMedicine
    2024 | Journal article
    DOI: 10.1016/j.ebiom.2023.104953

    EID:

    2-s2.0-85181837483

    Part ofISSN: 23523964
    CONTRIBUTORS: Ruiz-Gabarre, D.; Vallés-Saiz, L.; Carnero-Espejo, A.; Ferrer, I.; Hernández, F.; Garcia-Escudero, R.; Ávila, J.; García-Escudero, V.

  • Involvement of the cellular prion protein in seeding and spreading of sarkosyl-derived fractions of Alzheimer´s disease in Prnp mutant mice and in the P301S transgenic tauopathy mice model

    bioRxiv
    2024 | Other
    DOI: 10.1101/2024.01.20.576414

    EID:

    2-s2.0-85184321414

    Part of ISSN: 26928205
    CONTRIBUTORS: Sala-Jarque, J.; Gil, V.; Andrés-Benito, P.; Lidón, L.; Yanac-Huertas, R.E.; López-León, C.F.; Hernández, F.; Ávila, J.; Lanciego, J.L.; Soriano, J. et al.

Konrad Talbot | Alzheimer’s Disease | Best Researcher Award

Published on by Cognitive Scientist Awards

Assos. Prof. Dr. Konrad Talbot | Alzheimer’s Disease | Best Researcher Award

Dr. Konrad Talbot is a distinguished neuroscientist and Associate Professor at Loma Linda University School of Medicine, serving in the Departments of Neurosurgery, Pathology & Human Anatomy, and Basic Sciences since 2018. He specializes in investigating the pathogenesis and treatment of neurodegenerative and psychiatric disorders, particularly focusing on brain insulin resistance in Alzheimer’s and Parkinson’s diseases. With a Ph.D. in Physiological Psychology from UCLA and extensive postdoctoral training at the University of Pennsylvania, Dr. Talbot has held faculty and research positions at leading institutions such as Cedars-Sinai, UCLA, and UPenn. He is a highly cited researcher (H-index: 34, 9341 citations), with significant NIH and international grant support. He also serves as an editorial board member, reviewer, and invited speaker at global conferences. His work has influenced both fundamental neuroscience and the development of therapeutic strategies for brain diseases.

Profile

🎓 Education

Dr. Konrad Talbot completed his undergraduate (B.A.), master’s (M.A.), and doctoral (Ph.D.) degrees in Psychology with a specialization in Physiological Psychology at the University of California, Los Angeles (UCLA). His academic path reflects a deep commitment to understanding the biological underpinnings of behavior and brain function. He also received formal teaching certification from UCLA’s Instructor Development Program in 1992. His postdoctoral training included pivotal roles at the University of Pennsylvania’s Department of Pathology and Laboratory Medicine and the Center for Neurodegenerative Disease Research (1997–2001), where he developed expertise in brain autopsy and pathology. He furthered his technical capabilities through advanced training in quantitative fluorescence microscopy at Mount Desert Island Biological Laboratory in 2007. His broad educational background forms a strong foundation for his interdisciplinary research and teaching roles across psychology, neurobiology, pathology, and medical sciences.

🧪 Experience

Dr. Talbot’s academic journey spans over three decades, beginning as an Assistant Professor at Mount St. Mary’s College and St. Olaf College, where he taught psychology and mentored numerous students. He transitioned into intensive research roles at the University of Pennsylvania (UPenn) from 1997 to 2012, ascending from postdoctoral investigator to senior research investigator and research faculty. He later held associate research professorships at Cedars-Sinai Medical Center and UCLA. Since 2018, he has served as Associate Professor at Loma Linda University. Dr. Talbot has authored influential studies on brain insulin resistance, taught neuroanatomy to medical residents, supervised postdoctoral and undergraduate research projects, and served in various academic leadership and committee roles. In addition to his research and teaching, he has contributed editorial expertise to high-impact journals and consulted on landmark neuroanatomical atlases. His career reflects a blend of teaching excellence, pioneering research, and interdisciplinary leadership.

🏅 Awards and Honors

Dr. Talbot’s contributions have been widely recognized through prestigious awards and honors. In 2003, he received the T.L.L. Temple Foundation Discovery Award from the Alzheimer’s Association for his groundbreaking work on brain insulin resistance. He was honored as a co-dedicatee of the influential neuroscience text The Mouse Brain in Stereotaxic Coordinates (2008 edition), highlighting his impact on anatomical brain mapping. In 2020, he was inducted into the Sigma Chi Scientific Research Honor Society. His professional affiliations include long-standing memberships with the Society for Neuroscience, Alzheimer Research Forum, Schizophrenia Research Forum, and ISTAART (International Society to Advance Alzheimer Research and Treatment). He has played leadership roles in organizing major scientific conferences, chaired institutional committees, and served on advisory panels. His editorial contributions and invited lectures worldwide further underscore the scientific community’s high regard for his research excellence and thought leadership.

🔬 Research Focus

Dr. Talbot’s research centers on identifying and targeting mechanisms underlying neurodegenerative and psychiatric diseases, with a special emphasis on insulin resistance in the brain. He has pioneered investigations showing that brain insulin resistance plays a critical role in Alzheimer’s and Parkinson’s disease pathogenesis. His NIH-funded work explores the therapeutic potential of incretin receptor agonists—an emerging class of antidiabetics—in reducing brain insulin resistance and improving cognitive function. His collaborative projects with institutions like CUNY, UCLA, and the University of Washington focus on both human brain tissue analysis and preclinical models. Past research includes the molecular biology of schizophrenia, especially dysbindin-related pathways. He holds a U.S. patent application on methods for treating brain insulin resistance, signaling the translational potential of his findings. Dr. Talbot’s research integrates neuropharmacology, pathology, neuroanatomy, and clinical neuroscience, aiming to develop disease-modifying treatments that can halt or reverse progression in cognitive and psychiatric disorders.

✅ Conclusion

Dr. Konrad Talbot is an accomplished neuroscientist whose multidisciplinary work in brain insulin resistance has significantly advanced understanding and treatment approaches for Alzheimer’s and Parkinson’s diseases, blending rigorous research, impactful teaching, and translational innovation.

Publications

Faheem Arshad | Cognitive Neurosciences | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Faheem Arshad | Cognitive Neurosciences | Best Researcher Award

Dr. Faheem Arshad is an Assistant Professor of Neurology at the National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru. A leading cognitive neurologist in India, he specializes in dementia and neurodegenerative disorders. He played a pivotal role in establishing India’s first cognitive disorders registry at NIMHANS, integrating clinical and research excellence. Dr. Arshad is a Senior Atlantic Fellow for Equity in Brain Health at the University of California, San Francisco (UCSF), and the first fellow from South Asia. His research integrates neurogenetics, biomarkers, imaging, and clinical trials, with a focus on inclusivity and low-literacy populations. He actively contributes to national and international collaborations and holds leadership roles within Indian and global neurology communities. Committed to early diagnosis, caregiver support, and prevention strategies, his work aims to improve brain health equity in diverse settings. His ongoing studies explore social interaction, bilingualism, and digital tools in dementia management.

Profile

Education 🎓

Dr. Arshad received his foundational training in Internal Medicine (MD, 2014) at Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Kashmir. He served as Registrar in Internal Medicine at AIIMS, New Delhi until 2016. He pursued advanced neurological training at the National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, earning a DM in Neurology (2019) and completing a Post-Doctoral Fellowship in Cognitive Neurosciences (2020). He furthered his expertise with a prestigious international fellowship in Global Brain Health Equity at the Global Brain Health Institute (GBHI), University of California, San Francisco (UCSF), USA in 2021. Dr. Arshad also holds the MRCP(UK) Neurology credential (2020), reflecting global competence. His multidisciplinary training spans cognitive neurology, imaging, biomarkers, and dementia prevention, equipping him with a holistic approach to brain health research and patient care.

Experience 👨‍🏫

Dr. Faheem Arshad’s professional journey spans over a decade of clinical, academic, and research excellence. He is currently Assistant Professor of Neurology at NIMHANS, Bengaluru, where he has led initiatives in cognitive neurology since 2021. His early training included roles as Junior and Senior Resident in Internal Medicine at SKIMS and AIIMS, followed by Neurology Residency and Postdoctoral Fellowship at NIMHANS. He became a faculty leader and Convener of the Cognitive Neurology subsection of the Indian Academy of Neurology in 2023. Internationally, he served as an Atlantic Fellow at UCSF’s GBHI (2020–2021), developing leadership in brain health equity. Dr. Arshad is a member of the American Academy of Neurology and other prestigious forums. He has published widely, initiated clinical trials, and built registries that bridge clinical insights with translational research. His work integrates social science, neurobiology, and global health in addressing dementia across underserved populations.

Awards & Recognitions 🏅

Dr. Faheem Arshad has received numerous recognitions for his contributions to neurology and dementia research. He was awarded the Bursary Award at the TSS International Neuropsychiatry Conference (2018) for his work on social cognition in Frontotemporal Dementia. As the first South Asian to become a Senior Atlantic Fellow for Equity in Brain Health at UCSF’s GBHI, he has been globally recognized for championing equity in dementia care and research. His appointment as Convener of the Cognitive Neurology subsection by the Indian Academy of Neurology in 2023 highlights his leadership within the national academic community. He holds the MRCP(UK) in Neurology and is an active member of prestigious societies, including the American Academy of Neurology. These honors reflect his ongoing commitment to research innovation, community-based care models, and international collaboration in the field of neurodegenerative disorders.

Research Interests 🔬

Dr. Faheem Arshad’s research focuses on dementia, particularly Frontotemporal Dementia (FTD), Alzheimer’s Disease, and related neurodegenerative conditions. He investigates cognitive reserve, biomarkers, social cognition, neuroimaging, and bilingualism in dementia resilience. His landmark projects include exploring the role of social interaction in FTD (GBHI-AA), plasmapheresis in Alzheimer’s (ICMR), cognitive testing in low-literacy settings, and bilingualism’s impact on cognitive reserve (NIH-funded). He co-leads a SERB-funded project using speech features for early dementia detection and a DBT-funded imaging study for vascular dementia diagnosis. He established India’s first cognitive disorders registry at NIMHANS, integrating socio-demographics, imaging, and biomarker data. His work bridges clinical neurology and public health, emphasizing inclusive research for underrepresented populations. A strong advocate for clinical trials in LMICs, his studies integrate AI tools, cross-cultural data, and longitudinal analyses to improve early diagnosis and therapeutic strategies in dementia care.

Publications

Vahid Rashedi | Alzheimer’s disease | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Vahid Rashedi | Alzheimer’s disease | Best Researcher Award

Dr. Vahid Rashedi 👨‍⚕️, an esteemed Assistant Professor of Gerontology at the University of Social Welfare and Rehabilitation Sciences 🇮🇷, has made outstanding global contributions in aging, cognition, and psychogeriatrics 🌍🧠. With a Ph.D. in Gerontology (2017) 🎓 and extensive editorial duties across high-impact journals 📚, he’s actively involved as a Senior Collaborator with the Global Burden of Disease Project at IHME, University of Washington 🇺🇸. Recognized as a Top 1% scientist by Stanford University in 2024 🏅, he combines academic excellence, innovation, and impactful research. His interdisciplinary work spans gerontology, rehabilitation, mental health, and cognitive science, cementing his status as a global leader in aging research 🌐💡.

Profile

Education 🎓

Dr. Rashedi began his academic path with a Bachelor’s and Master’s degree in Rehabilitation Sciences 🎓🦾, focusing on geriatric care and assistive technology. He earned his Ph.D. in Gerontology with distinction in 2017 🥇, building expertise in psychogeriatrics, mental health, and cognitive decline. His academic training was rooted in interdisciplinary frameworks linking medicine, psychology, and social work 🔬💬. This diverse education empowered him to bridge clinical insights with research, enabling innovative health solutions for elderly populations 👵👴. He complements formal education with global scientific memberships and ongoing collaborations with prestigious institutes, such as IHME 🌎, emphasizing lifelong learning and cutting-edge research.

Experience 👨‍🏫

Dr. Rashedi has over a decade of rich academic and research experience, currently serving as Assistant Professor at the University of Social Welfare and Rehabilitation Sciences 🏫. Since 2019, he has been a Senior Collaborator at IHME, University of Washington, contributing to the Global Burden of Disease project 📊🌐. He has authored 126 indexed journal articles 📑, published a book 📖, and holds four patents, including rehabilitation innovations like the vibrating ankle-foot orthosis 🦿. He is a prolific editorial board member and associate editor for over 10 international journals 📘🖋️. His work in psychogeriatrics and cognition has garnered global recognition, highlighting his leadership and mentoring roles 👨‍🏫🏅.

Awards & Recognitions 🏅

Dr. Rashedi is recognized globally for his scientific excellence, notably ranked in the Top 1% of scientists worldwide by Stanford University in 2024 🌟📈. He holds editorial roles in Frontiers, CGJ, and the Journal of Gerontology, reflecting scholarly esteem 📚. He is a trusted reviewer for numerous high-impact journals and was honored with national and international awards 🥇. His patented inventions in geriatric rehabilitation demonstrate a blend of innovation and clinical value 💡🏥. His GSA, APA, and ISTAART memberships validate his international standing 👏🌐. These honors underscore his unwavering dedication to improving elderly lives through evidence-based science and collaboration 🤝

Research Interests 🔬

Dr. Rashedi’s research delves into psychogeriatrics, mental health, and cognitive disorders in aging populations 🧠👴. As part of the Global Burden of Disease team at IHME 🌍, he contributes to global health analytics, shaping international aging policies 📊. His innovations include assistive devices with therapeutic functions, bridging technology and clinical rehabilitation 🛠️⚙️. With 63 research projects and over 26,000 citations 🔍📈, his scholarly output is extensive and impactful. He leads investigations on dementia, geriatric depression, and cognitive resilience, supported by his roles in editorial boards and scientific societies 🧬📘. His mission is to translate research into real-world health solutions for aging communities 🌟🩺.

Publications 

LUCIANO VITORINO | Cognitive Aging | Cognitive Aging Excellence

Published on by Cognitive Scientist Awards

Dr. LUCIANO VITORINO | Cognitive Aging | Cognitive Aging Excellence

Dr. Luciano Magalhães Vitorino, Ph.D., RN 🇧🇷 is a dedicated professor at the Faculty of Medicine of Itajubá, Brazil 🏥, with expertise in nursing, gerontology, spirituality, and health 🌱. He has built a multidisciplinary academic and research career blending healthcare, cognition, and spirituality 🧠🙏. With over 1,500 citations 📚 and extensive teaching roles in medicine and nursing 🩺, he leads the Research Center and the Assessment Center at FMIT, actively contributing to the Research Ethics Committee 👨‍🔬. His international academic collaborations, including the University of Alberta 🇨🇦, reflect his global engagement 🌍. A recognized academic voice, he served as Guest Editor for Frontiers in Psychiatry 📰 and holds memberships across academic platforms 📊. Through education, mentorship, and pioneering research, Dr. Luciano is influencing healthcare for the aging population 💡👴👵.

Profile

Education 🎓

Dr. Luciano holds a Postdoctoral Fellowship in Cognition, Spirituality, and Aging from UFJF (2017–2019) 🧘‍♂️🧠, a Ph.D. and M.Sc. in Quality of Life & Spiritual Health from UNIFESP (2012–2016) 📖, and a B.Sc. in Nursing from Faculty of Nursing Wenceslau Braz (2006) 🩺. He specialized in Urgency and Emergency Care (2008–2010) ⛑️. His Ph.D. work was guided by experts from UNIFESP and the University of Alberta 🇨🇦, exploring spiritual/religious coping among older adults. His dissertation and thesis focused on quality of life and religious coping in nursing homes and community settings 🙏🏘️. His postdoctoral project assessed spirituality’s influence on cognitive decline in aging populations 🧓. This unique education, combining nursing, public health, and spirituality, positions him as a thought leader in holistic geriatric care

Experience 👨‍🏫

Dr. Luciano is a full-time assistant professor at FMIT since 2018 👨‍🏫. He coordinates both the Research Center (since 2022) and Assessment Center (since 2022), and is a long-standing member of the Research Ethics Committee (since 2019) 🧪📋. He previously taught at Faculty of Nursing Wenceslau Braz (2007–2012), Medical School of Itajubá (2013–2014), and Federal University of São Paulo (2013) 👨‍⚕️📘. He’s also guided health residency programs and coordinated caregiver training for elderly individuals 👵👨‍⚕️. As Guest Editor of Frontiers in Psychiatry (2022–2023), he shaped international discussions on spirituality and health 🗞️🕊️. His teaching subjects include Epidemiology, Geriatrics, Medical Semiology, and Spirituality & Health 🧬🩻. His roles reflect a passion for interdisciplinary health sciences and dedication to ethical, evidence-based care 🌟.

Awards & Recognitions 🏅

Dr. Luciano’s impactful research and teaching have earned him numerous citations across Scopus (h-index 13, 525 citations), Web of Science (h-index 11, 454 citations), Google Scholar (h-index 20, 1,506 citations) 📈, and ResearchGate (h-index 16, 864 citations) 🧑‍🔬. His inclusion as Guest Editor for Frontiers in Psychiatry (2022–2023) showcases recognition in global academic communities 🌍. He’s contributed to leading Brazilian and international institutions like UNIFESP, UFJF, and the University of Alberta 🇧🇷🇨🇦. Through strong publication records and global collaborations, he’s established himself as an authority on spiritual health in aging 🚀📚. His profile on Google Scholar, ORCID, and LinkedIn reflects international engagement and scholarly distinction 🌐🎖️.

Research Interests 🔬

Dr. Luciano’s research bridges Geriatrics, Gerontology, Spirituality and Mental Health, and AI in Healthcare 🧓🧠💻. His central interest lies in understanding how spirituality and religiosity affect cognitive aging and quality of life 🌿🧘‍♂️. His postdoctoral research—a 4-year longitudinal study—explored how spiritual coping impacts cognitive decline in community-dwelling elders 🧪🕯️. He also investigates medical education, primary healthcare, and interdisciplinary training 🩺📘. As AI transforms healthcare, he examines its integration with geriatric care and spiritual health frameworks 🤖❤️. Through mixed-methods research and international collaboration, he aims to personalize elderly care and mental wellness using both humanistic and data-driven approaches 📊✨.

Publications 

Gerd Fabian Volk | Cognitive Rehabilitation | Outstanding Scientist Award

Published on by Cognitive Scientist Awards

Dr. Gerd Fabian Volk | Cognitive Rehabilitation | Outstanding Scientist Award

apl. Prof. Dr. med. habil. Gerd Fabian Volk (👶1978, Wertheim am Main) is a leading German otolaryngologist 👨‍⚕️, currently serving as Senior Physician and Head of the Facial Nerve Center in Jena 🏥. With a deep commitment to clinical excellence, academic teaching 📚, and innovative research 🧪, he has significantly contributed to the fields of neurolaryngology, facial nerve disorders, and ultrasound diagnostics 🧠🗣️. His work bridges cutting-edge imaging 🖼️ and functional diagnostics for head-neck disorders. Living in Jena with his family 👨‍👩‍👧‍👧, he actively supports patient education through YouTube 📹, coordinates national workshops, and advocates for interdisciplinary collaboration 🤝. Volk is a respected speaker 🎤, faculty member at international dissection courses ✂️🧠, and an initiator of hybrid symposia. He balances leadership with education, translating research into real-world clinical impact 🌍💡.

Profile

Education 🎓

Studied human medicine at Westfälische Wilhelms Universität Münster (1999–2006) 🎓🩺, earning his state exam. In 2007, he completed his doctorate (Dr. med.) with a thesis on axonal regeneration in retinal ganglion cells in primates and rats 🧬🐒🐀. He achieved board certification in ENT (2012) 👂👃🧠 and earned his postdoctoral qualification (habilitation) in 2017 with pioneering research on quantitative imaging of facial muscles 🖼️💪. His venia legendi was granted by Friedrich Schiller University Jena in otorhinolaryngology 📜👨‍🏫. Further qualifications include DEGUM Level II (2018) for ultrasound, clinical trial leadership certification (2009), animal research leadership certification (2002), and interdisciplinary leadership training at UKJ 🏅📊. His broad educational background underpins his medical, scientific, and didactic work, combining clinical care, diagnostics, and teaching for the next generation of ENT specialists 👨‍⚕️👩‍⚕️👨‍🏫.

Experience 👨‍🏫

Since 2013, Dr. Volk leads the Facial Nerve Center in Jena and co-founded the Tinnitus Center 👨‍⚕️🔊. He is currently Senior Physician at the ENT Department, University Hospital Jena and member of the steering committee for the Center for Rare Diseases Jena (since 2024) 🧩🧬. He previously held rotational research fellowships in radiology and neurology (2008–2013) and has organized national ENT courses since 2009 🧠🎓. With consistent academic teaching since 2012, he has led cadaver dissection courses, neurolaryngology workshops, and ultrasound diagnostics trainings 🧑‍🏫💻. He is an active contributor to ethics commissions and rare disease networks 👥⚖️. His work merges clinical ENT practice, surgical skill, and educational outreach through digital platforms (e.g., YouTube, www.lemg.org) 🌐📹. A devoted mentor, he organizes monthly PhD symposia and integrates hybrid teaching formats, balancing high-level medical care with forward-thinking academic initiatives 📚🏥🎯.

Awards & Recognitions 🏅

Recipient of multiple national prizes, including the 1st Poster Prize by the German Society for Ultrasound in Medicine (2019) 🥇📊 for Parkinson-related facial muscle imaging, and the DEGUM Head-Neck Section Award for his habilitation research (2018) 🧠🏅. Awarded competitive IZKF research fellowships in neurology and radiology (2008–2013) 🧬🔬. Recognized leader in rare disease diagnostics and member of Germany’s CRANIO-Net for rare craniofacial disorders (since 2022) 🧩👶. Since 2020, he contributes to the Ethics Commission of the University Hospital Jena ⚖️. He is speaker for ENT indications in the Botulinumtoxin Working Group of the German Society of Neurology (since 2022) 💉🧠. Nominated for professorial posts in Bielefeld, Halle, and Charité Berlin between 2019–2023 🏛️📚. Volk’s sustained excellence across clinical care, diagnostics, research, and education has earned him national recognition and leadership roles in academic ENT medicine 🧠🏥✨.

Research Interests 🔬

Prof. Volk’s research centers on facial nerve diagnostics and therapy 🧠🧑‍⚕️, neurolaryngology, and ultrasound imaging of head-neck structures 🖼️. He specializes in quantitative imaging of facial muscles for conditions like facial paralysis and Parkinson’s disease 🤖🧠. His work combines clinical neurophysiology, MRI analysis, and laryngeal electromyography (LEMG) 📈💬. He also pioneers educational innovations in hybrid learning, simulation-based teaching, and cadaver dissection techniques for ENT and neurology professionals 🧑‍🏫🧪. Through platforms like www.lemg.org and dedicated YouTube channels 📹, he disseminates knowledge on advanced diagnostics such as salivary duct endoscopy, voice disorders, and botulinum toxin use 💉. A strong advocate for interdisciplinary networks and rare disease research, he leads initiatives in patient-centered care, including organizing the “Fazialis-Nerv-Tag” and supporting patient education 🤝❤️. His translational research aims to enhance diagnostic precision and develop novel rehabilitation strategies for complex craniofacial disorders 🧬🔧.

Publications 

  • Electromyography as an Objective Outcome Measure for the Therapeutic Effect of Biofeedback Training to Reduce Post-Paralytic Facial Synkinesis

    Healthcare
    2025-03-04 | Journal article
    DOI: 10.3390/healthcare13050550
    CONTRIBUTORS: Isabell Hahnemann; Julia Fron; Jonas Ballmaier; Orlando Guntinas-Lichius; Gerd Fabian Volk

  • Evaluation of the Effects of an Electromyography-Based Bio-Feedback Training of Patients with Post-Paralytic Facial Synkinesis Using Electromyography Amplitudes as Objective Outcome Measure

    2024-12-16 | Preprint
    DOI: 10.20944/preprints202412.1326.v1
    CONTRIBUTORS: Isabell Hahnemann; Julia Fron; Jonas Ballmaier; Orlando Guntinas-Lichius; Gerd Fabian Volk

  • Deceleration of denervated facial muscle atrophy through functional electrical stimulation: a sonographic quantification in patients with facial nerve paralysis

    European Journal of Translational Myology
    2024-11-13 | Journal article
    DOI: 10.4081/ejtm.2024.13162
    CONTRIBUTORS: Gabriel Meincke; Johannes Krauß; Maren Geitner; Anna-Maria Kuttenreich; Dirk Arnold; Jonas Ballmaier; Thomas Lehmann; Winfried Mayr; Orlando Guntinas-Lichius; Gerd Fabian Volk

Jeevitha Gowda R | Cognitive impairment | Best Researcher Award

Published on by Cognitive Scientist Awards

Ms. Jeevitha Gowda R | Cognitive impairment | Best Researcher Award

Assistant Professor, Alliance University, United Kingdom

🧠 Dr. Jeevitha Gowda R is a dedicated research scholar specializing in cognitive neuroscience and public health, with a strong focus on dementia prevention. She has expertise in developing cognitive screening tools, conducting neuropsychological assessments, and designing neuroscience-based interventions to enhance brain health. Currently serving as a Guest Faculty and Research Associate, she is passionate about bridging research with real-world applications. With proficiency in EEG, ERP, and data analysis, her work emphasizes cognitive aging, behavioral psychology, and mental well-being. Her research contributions include multiple conference presentations, publications, and cognitive training programs. She has received prestigious recognitions, including Best Paper Awards and research fellowships. Her commitment extends to community mental health programs, where she collaborates with NGOs and research institutions. Through her work, she aims to advance cognitive neuroscience and improve public health outcomes. 📚🔬

Profile

Education 🎓

🎓 Dr. Jeevitha Gowda R holds a Ph.D. in Cognitive Neuroscience and Public Health from Ramaiah University of Applied Sciences, Bengaluru (Thesis Submitted), focusing on developing cognitive tools for early dementia detection in primary healthcare settings. She earned a Master’s in Cognitive Neuroscience from JSS Academy of Higher Education, Mysuru (2018), ranking among the top 3 students, with coursework in neural cognition, psychological assessment, and clinical interventions. Her dissertation explored mental fatigue due to sleep deprivation using EEG and ERP. She completed her Bachelor’s in Life Sciences from JSS College for Women, Mysuru (2016), excelling in biochemistry, microbiology, and environmental psychology. Additionally, she trained at the Defence Institute of Psychological Studies (DRDO) and Narayana Health, Bengaluru, gaining hands-on experience in EEG, neuropsychological assessments, and cognitive therapy. Her interdisciplinary education combines neuroscience, psychology, and public health, preparing her for impactful research and innovation in brain health. 🧠📖

Experience 👨‍🏫

💼 Dr. Jeevitha Gowda R has extensive experience as a Research Associate at the Centre for Integrative Health and Well-Being (2020–Present), where she develops neuropsychological intervention tools and conducts cognitive behavioral therapy (CBT) programs. She also serves as a Senior Research Associate at Brighter Minds, focusing on cognitive enhancement and neuroscience-based training programs. As a Guest Lecturer at Ramaiah University of Applied Sciences (2021–Present), she teaches biostatistics, neurophysiology, and psychology. Her past clinical internships at DRDO and Narayana Health provided her with hands-on expertise in EEG, ERP, and neuropsychological assessments. She has conducted research on cognitive impairment, dementia screening, and sleep deprivation’s effects on cognition. Additionally, she has authored 50+ neuroscience articles, presented at international conferences, and collaborated with NGOs for mental health awareness. Her diverse experience integrates academic, clinical, and research-based expertise to advance cognitive neuroscience and public health. 🏥📊

Research Interests 🔬

🔬 Dr. Jeevitha Gowda R’s research bridges cognitive neuroscience, psychology, and public health, focusing on early dementia detection, cognitive aging, and neuropsychological interventions. She specializes in developing culturally relevant cognitive screening tools for primary healthcare, improving accessibility to dementia diagnostics. Her work explores neuropsychological assessments, EEG-based cognitive analysis, and behavioral interventions for enhancing mental well-being. She has conducted studies on sleep deprivation, cognitive impairment, and neurofeedback therapy. She collaborates with institutions like DRDO, Narayana Health, and Brighter Minds to implement neuroscience-driven programs. Her research extends to the psychological well-being of dementia caregivers, neurocognitive training for brain health, and integrating technology into mental health solutions. Through interdisciplinary studies and global research collaborations, she aims to advance early dementia detection methods and improve cognitive health strategies. Her work contributes to policy-making, clinical psychology, and public health initiatives. 🏥📊

Awards & Recognitions 🏅

🏆 Dr. Jeevitha Gowda R has received multiple accolades for her contributions to cognitive neuroscience and public health research. She won the Best Paper Award at the Epidemiology Foundation of India Conference (2023, Goa) for her groundbreaking work on dementia screening. Her research paper on cognitive tool validation earned a Special Mention at the International Dementia Conference (DEMCON-2024, IISC Bangalore). During her master’s, she ranked among the top 3 dissertations at JSS Academy of Higher Education. She was awarded the Senior Research Fellowship (SRF) by Ramaiah University of Applied Sciences (2022–2024) for her Ph.D. research. She has also secured research grants for projects on dementia detection and cognitive enhancement. Recognized for her impactful contributions, she collaborates with prestigious institutions, including DRDO and Narayana Health, to advance neuropsychological research. Her work continues to shape innovations in mental health and aging. 🎖️🧠

Publications 📚

  • Jeevitha Gowda R, Anish Mehta, Krishnamurthy Jayanna. (2025).
    Dementia: A Public Health Challenge in India. South Eastern European
    Journal of Public Health, 29–43. Retrieved from
    hps://www.seejph.com/index.php/seejph/article/view/3295 (Scopus)

  • Jeevitha Gowda R. The Impact of Cultural Beliefs and Stigma on
    Dementia Care and Diagnosis: A Scoping Review, 25 November 2024,
    PREPRINT (Version 1) available at Research Square
    hps://doi.org/10.21203/rs.3.rs-5519592/v1
  • Jeevitha Ramesh, Parimala Guruprasad (2024) Factors Affecting the
    Psychological Well-Being of Caregivers of Dementia Patients: A
    Thematic Review. Journal of Neurology Research Reviews & Reports.
    SRC/JNRRR-260
  • Development and Validation of Cognitive Screening Tools for
    Dementia Detection in Primary Care Seings: An Exploratory Pilot
    Study – Under review at International Journal of Geriatric Psychiatry.
    (Corresponding Author)
  • Burden of Cognitive Impairment Including Dementia, and Associated
    Risk Factors Among the Rural Population of South Karnataka, India –
    Under review at Journal of Public Health Research. (Corresponding
    Author)
  • Impact of Training Module on Lifestyle and Healthy Behaviours: An
    Exploratory Pilot in India – Under review at Journal Explore.
    (Co-Author)

Suleyman Yildizdal | Craniosynostosis | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Suleyman Yildizdal | Craniosynostosis | Best Researcher Award

 

 

Profile

Education

He completed his education at Org. Kenan Evren School from 2000 to 2008, followed by Gaziantep Anadolu High School from 2008 to 2012. He then pursued his medical training at Hacettepe University Faculty of Medicine from 2012 to 2018. After earning his medical degree, he continued his specialization in Plastic, Reconstructive, and Aesthetic Surgery as a resident at Hacettepe University Faculty of Medicine from November 2018 to February 2024. In April 2024, he joined Ankara Research and Training Hospital, where he continues to work in the Department of Plastic, Reconstructive, and Aesthetic Surgery.

 

Work experience

He has participated in various courses and workshops to enhance his expertise in plastic, reconstructive, and aesthetic surgery. He attended the Resident Ethics Course at Hacettepe University’s Department of History of Medicine and Medical Ethics on January 10-11, 2019. He also completed the 5th Basic Residency School organized by the Turkish Society of Plastic, Reconstructive, and Aesthetic Surgery in Bolu, Turkey, from January 22-25, 2020. Further advancing his skills, he took part in the 15th Advanced Residency School in Antalya, Turkey, from April 20-24, 2023. Additionally, he attended the 1st Cadaver Course of Craniofacial Anomaly and Maxillofacial Surgery at Hacettepe University on September 3-4, 2022, and the 1st Cadaver Course of Orthognathic Surgery at Koc University Hospital in Istanbul, Turkey, on September 7-8, 2022.

In addition to his clinical and surgical training, he has contributed to academic literature by co-authoring book chapters. He co-wrote Age-Related Changes in Trunk Aesthetics in Beauty, Aging, and Anti-Aging (1st ed., Elsevier, 2022) alongside G. G. Üstün and S. Yıldızdal. He also contributed to Dudak ve Damak Yarıkları Hacettepe Ekip Yaklaşım, co-authoring “Apert and Crouzon Syndrome” with İbrahim Vargel.

Awards

He has achieved remarkable academic success, securing 16th place in the National Examination for Specialty in Medicine among over 18,000 participants. Additionally, he ranked 571st in the National Student Selection and Placement Examination out of more than 2 million candidates.

He has actively participated in national meetings within his field, contributing to discussions and advancements in plastic, reconstructive, and aesthetic surgery. He attended the 41st National Turkish Plastic Reconstructive and Aesthetic Surgery Meeting in Samsun, Turkey, from October 26-30, 2019. He also participated in the National Turkish Plastic Reconstructive and Aesthetic Surgery Eastern Mediterranean Meeting on Cleft Lip and Palate, held in Gaziantep, Turkey, from February 7-9, 2020. Furthermore, he attended the 43rd National Turkish Plastic Reconstructive and Aesthetic Surgery Meeting in Antalya, Turkey, from November 10-14, 2021.

 

Publication

Michal Schwartz | Neurodegenerative diseases | Best Researcher Award

Published on by Cognitive Scientist Awards

Prof Dr. Michal Schwartz | Neurodegenerative diseases | Best Researcher Award

Michal Schwartz (born 1 January 1950) is a professor of neuroimmunology at the Weizmann Institute of Science. She is active in the field of neurodegenerative diseases, particularly utilizing the immune system to help the brain fight terminal neurodegenerative brain diseases, such as Alzheimer’s disease and dementia.[3][1]

Schwartz’s studies have shown that the immune system supports a healthy brain’s function and is vital for healing and protecting the brain in case of injury or disease.[4]

Schwartz coined the term protective autoimmunity[5] and discovered roles for immune cells in repair and neurogenesis. She has been the elected chair of the International Society of Neuroimmunology (ISNI) since 2016.[6]

In 2023 Schwartz received the honorary Israel Prize for Life Sciences.

 

Profile

Education

Schwartz gained her Bachelor of Science in chemistry at the Hebrew University of Jerusalem in 1972. She received her Ph.D in Immunology in 1977 at the Weizmann Institute of Science, where she would later spend the majority of her career. She also spent time at the University of Michigan, Ann Arbor, researching nerve regeneration.[when?

 

Work experience

At the Weizmann Institute, she progressed from senior scientist in the Department of Neurobiology to full professor in 1998, and was then awarded the Maurice and Ilse Katz Professorial Chair in Neuroimmunology in 2016.[7] Schwartz’s work in neuroimmunology has encompassed a wide range of pathologies in the central nervous system (CNS), including injury, neurodegeneration, mental dysfunction, and aging. She coined the term protective autoimmunity and demonstrated the role of immune cells such as macrophages and T cells in spinal cord repair. She also identified specific brain areas for ‘cross talk’ between the CNS and the immune system. This cross-talk is important for recruiting immune cells and maintaining a healthy brain, and the disruption of this cross-talk can play a role in brain aging and neurodegenerative disease. She also showed this role in pregnancy and fetal brain development, where immune disruption in the mother can be linked to neurodevelopmental disorders in their children. Another focus of her work has been on repurposing cancer immunotherapies such as PD-1 blockers to treat neurodegenerative disorders, such as Alzheimer’s disease.

Macrophages

The Schwartz team discovered that bone marrow-derived macrophages are needed for central nervous system (CNS) repair. The brain-resident myeloid cells (the microglia), and infiltrating monocyte-derived macrophages are not redundant populations, despite their myeloid phenotype, and display distinct functions in resolution of brain inflammation.[8][9][10]

Autoimmunity

In her research, Schwartz discovered that the ability to cope with sterile CNS injuries requires support in the form of an adaptive immune response mediated by CD4+ T cells that recognize CNS antigens. She coined the concept of protective autoimmunity, to distinguish this response from autoimmune disease, in which the anti-self response escapes control. Over the years, it became clear that adaptive immunity is needed to facilitate the recruitment of immunoregulatory cells, including bone marrow-derived macrophages and FoxP3 regulatory T cells, though the balance between regulatory T cells and effector memory cells is different in the periphery versus the brain.[11][12][13]

Brain Homeostasis

Schwartz’s team discovered the role of adaptive systemic immune cells, and specifically T cells recognizing brain antigens (Protective autoimmune T cells), in supporting the cognitive capacity of the healthy brain, for lifelong neurogenesis, and functional brain plasticity. These observations paved the way for numerous additional discoveries in which the brain-immune axis was described.[14][15][16]

The Choroid Plexus

Schwartz’s team identified the brain’s choroid plexus (CP) within the blood-cerebrospinal fluid barrier as an immunological interface between the brain and the immune system. It serves as a niche that hosts immune cells, and as a physiological entry gate for leukocytes. Focusing on this unique niche within the brain led the Schwartz group to propose that IFN-γ holds the key to regulating CP gateway activity. Her team further showed that in brain aging and neurodegenerative diseases (studied using both mouse models and human samples), dysfunction of this interface is determined both by signals originating in the brain, and signals from the aged immune system, which led to the identification of Type-I Interferon (IFN-I) at the CP as a negative player, affecting the fate of the aging brain in general, and of microglia, in particular. A similar IFN-I signature at the CP was subsequently discovered by others in Alzheimer’s disease and in the postmortem brains of infected patients who died from COVID-19.[17][14][10]

Immunotherapy

The discovery that adaptive immunity plays a key role in brain function and repair, the need for bone marrow-derived macrophages to resolve local brain inflammation, the fact that Alzheimer’s disease (AD) and all forms of dementia are mainly age-related diseases, and the fact that the immune system is particularly affected by aging all led Schwartz to propose a new treatment for combating dementias. Schwartz suggested empowering systemic immunity, using a form of immunotherapy by modestly blocking the inhibitory immune checkpoint PD1/PD-L1 pathway.[citation needed] This treatment drives an immune-dependent cascade of events, that allows the harnessing of bone marrow-derived macrophages and regulatory T cells to help clear toxic factors from the diseased brain, and to arrest the local inflammation, thereby providing a comprehensive multi-factorial therapy through modification of multiple elements that go awry in AD. Schwartz’s patents for developing such immunotherapy for AD are licensed to a small Biopharma company, Immunobrain Checkpoint. The company is awaiting a clinical trial in AD patients, supported in part by the National Institute of Aging, the US National Institutes of Health, and The Alzheimer’s Association.[18][19][20][21][22][23]

Publication

1. Rachmian N, Medina S, Cherqui U, Akiva H, Deitch D, Edilbi D, Croese T, Salame T, Peralta Ramos
J, Cahalon L, Krizhanovsky V, Schwartz M. 2024. Senescent microglia conserved in aging and
Alzheimer’s disease exhibit elevated TREM2 protein levels. Nat Neurosci 27: 1116-24
2. Tsitsou-Kampeli A, Suzzi S, Kenigsbuch M, Satomi A, Strobelt R, Singer O, Feldmesser E, Purnapatre
M, Colaiuta SP, David E, Cahalon L, Hahn O, Wyss-Coray T, Shaul Y, Amit I, Schwartz M. 2023.
Cholesterol 24-hydroxylase at the choroid plexus contributes to brain immune homeostasis. Cell Rep
Med: 101278
3. Suzzi, S. Croese T., Ravid A., Gold O., Clark A., Medina A., Kitsberg D., Adam M., Vernon K., Kohnert
E., Shapira I., Malitsky S., Itkin M., Brandis A., Mehlman T., Salame T., Colaiuta S., Cahalon L.,Slyper
M., Greka A., Habib N., Schwartz M. 2023. N-acetylneuraminic acid links immune exhaustion and
accelerated memory deficit in diet-induced obese Alzheimer’s disease mouse model 2023. Nat. Commun.
14:1293.
4. Kenigsbuch M, Bost P, Halevi S, Chang Y, Chen S, Ma Q, Hajbi R, Schwikowski B, Bodenmiller B, Fu
H, Schwartz M*, Amit I* (equal contribution, and corresponding authors). 2022. A shared diseaseassociated oligodendrocyte signature among multiple CNS pathologies. Nat Neurosci 25: 876-86.
5. Dvir-Szternfeld R, Castellani G, Arad M, Cahalon L, Colaiuta SP, Keren-Shaul H, Croese T, Burgaletto
C, Baruch K, Ulland T, Colonna M, Weiner A, Amit I, Schwartz M. 2022. Alzheimer’s disease
modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in
mouse model of amyloidosis. Nature Aging 2: 60-73 (citations:17).
6. Ben-Yehuda H, Arad M, Peralta Ramos JM, Sharon E, Castellani G, Ferrera S, Cahalon L, Colaiuta SP,
Salame TM, Schwartz M. 2021. Key role of the CCR2-CCL2 axis in disease modification in a mouse
model of tauopathy. Mol Neurodegeneration 16: 39. (citations:20).
7. Cohen M, Giladi A, Raposo C, Zada M, Li B, Ruckh J, Deczkowska A, Mohar B, Shechter R, Lichtenstein
RG, Amit I, Schwartz M. 2021. Meningeal lymphoid structures are activated under acute and chronic
spinal cord pathologies. Life Sci Alliance 4: e202000907.
8. Habib N, McCabe C, Medina S, Varshavsky M, Kitsberg D, Dvir-Szternfeld R, Green G, Dionne D,
Nguyen L, Marshall JL, Chen F, Zhang F, Kaplan T, Regev A, Schwartz M. 2020. Disease- associated
astrocytes in Alzheimer’s disease and aging. Nat Neurosci 23: 701-6. (citations:617).
9. Ben-Yehuda H, Matcovitch-Natan O, Kertser A, Spinrad A, Prinz M, Amit I, Schwartz M. 2020.
Maternal Type-I interferon signaling adversely affects the microglia and the behavior of the offspring
accompanied by increased sensitivity to stress. Mol Psychiatry 25: 1050-67 (Cover page).
10. Kertser A,Baruch K, Deczkowska A,Weiner A,Croese T, Kenigsbuch M,CooperI, Tsoory M,Ben- Hamo
S, Amit I, Schwartz M. 2019. Corticosteroid signaling at the brain-immune interface impedes coping with
severe psychological stress. Sci Adv 5: eaav4111. (citations:32).
11. Rosenzweig N, Dvir-Sternfeld R, Tsitsou-Kampeli A, Keren-Shaul H, Ben-Yehuda H, Weill-Raynal P,
Cahalon L, Kertser A, Baruch K, Amit I, Weiner A, Schwartz M. 2019. PD-1/PD-L1 checkpoint blockade
harnesses monocyte-derived macrophages to combat cognitive impairment in a mouse model of tauassociated dementia. Nat Commun. 10: 465. (citations:141).
12. Deczkowska A, Matcovitch-Natan O, Tsitsou-Kampeli A, Ben-Hamo S, Dvir-Szternfeld R, Spinrad A,
Singer O, David E, Winter RD, Smith KL, Kertser A, Baruch K, Rosenzweig N, Terem A, Prinz M,
Villeda S, Citri A, Amit I, Schwartz M. 2017. Mef2C restrains the microglial inflammatory response and
is lost in brain ageing in an IFN-I-dependent manner. Nat Commun 8: 717. (citations:212).
13. Cohen M, Ben-Yehuda H, Porat Z, Raposo C, Gordon S, Schwartz M. 2017. Newly formed endothelial
2
cells regulate myeloid cell activity following spinal cord injury via expression of CD200 ligand. J
Neurosci 37: 972-85.

Marcelo Luis Berthier | Neuroscience| Best Researcher Award

Published on by Cognitive Scientist Awards

Prof. Marcelo Luis Berthier | Neuroscience| Best Researcher Award

 

Unversidad de Málaga, Spain

Profile

Education

Marcelo Luis Berthier obtained his degree in Medicine (1972-1976) and completed residency training in Neurosurgery (1977-1980), later specializing in Neurology (1980). He served as a staff neurologist at the Institute of Neurological Research, FLENI, Buenos Aires, Argentina (1980-1989), before becoming a research fellow in the Department of Neurology at Clinic Hospital of Barcelona, Spain (1989-1990). From 1991 to 2000, he was a staff neurologist and physician in charge of the Behavioural Neurology Unit at the Clinic University Hospital of Malaga. He earned a PhD in Neuroscience (cum laude) from the University of Malaga and coordinated the Group of Behavioural Neurology and Dementia of the Spanish Neurological Society (2004-2006). In 2004, he founded and directed the Unit of Cognitive Neurology and Aphasia at the Centro de Investigaciones Médico-Sanitarias, University of Malaga, leading it until 2023. Additionally, he served as the director of the Consolidated Research Group on Cognitive Neuroscience: Aphasia and Related Disorders (UNCA, C-12) at the Instituto de Investigación Biomédica de Málaga (IBIMA – Plataforma BIONAND).

Work experience

Dr. Marcelo L. Berthier Torres has led and contributed to several groundbreaking research projects in cognitive neurology and aphasia. As a co-investigator, he participated in the Telerehabilitation in Aphasia project (2021-2023), which evaluated the effectiveness of telerehabilitation compared to face-to-face therapy and identified predictive biomarkers of response, funded by the Junta de Andalucía. He also served as the principal investigator for a study on the efficacy of combined treatment with donepezil, intensive rehabilitation, and transcranial direct current stimulation in chronic post-stroke aphasia (2016-2019), funded by the Instituto de Salud Carlos III. Additionally, he has contributed to the Proyectos de Generación de Conocimiento “Frontera”, an initiative under the FEDER Andalucía 2014-2020 program, which investigates brain biomarkers for individualized treatment approaches in chronic post-stroke aphasia

Areas of Research

Dr. Marcelo L. Berthier Torres has made significant contributions to the treatment of post-stroke aphasia and speech-language disorders. He conducted the first open-label and randomized, placebo-controlled, double-blind trials investigating the use of cognitive-enhancing drugs (donepezil and memantine) alone and in combination with standard aphasia therapy or intensive language-action therapy (ILAT) in chronic post-stroke aphasia. His pioneering studies stimulated international research on aphasia pharmacotherapy, leading to clinical translation. Today, donepezil and memantine, alone or combined with therapy, are widely used off-label for post-stroke aphasia and language disturbances associated with neurodegenerative disorders like Alzheimer’s disease and primary progressive aphasia.

Publication

  • Revisiting the boundaries of different altered accents profiles

    Cortex
    2025-03 | Journal article
    DOI: 10.1016/j.cortex.2025.01.001
    CONTRIBUTORS: Marcelo L. Berthier; Ignacio Moreno-Torres; Jo Verhoeven; Guadalupe Dávila

  • Turning the Spotlight to Cholinergic Pharmacotherapy of the Human Language System

    CNS Drugs
    2023-07 | Journal article
    DOI: 10.1007/s40263-023-01017-4
    CONTRIBUTORS: Guadalupe Dávila; María José Torres-Prioris; Diana López-Barroso; Marcelo L. Berthier

  • Pharmacotherapy for post-stroke aphasia: what are the options?

    Expert Opinion on Pharmacotherapy
    2023-07-24 | Journal article
    DOI: 10.1080/14656566.2023.2221382
    CONTRIBUTORS: Marcelo L. Berthier; Guadalupe Dávila

  • Brain structural and functional correlates of the heterogenous progression of mixed transcortical aphasia

    Brain Structure and Function
    2023-05-31 | Journal article
    DOI: 10.1007/s00429-023-02655-6
    CONTRIBUTORS: Diana López-Barroso; José Paredes-Pacheco; María José Torres-Prioris; Guadalupe Dávila; Marcelo L. Berthier

  • Controlling the past, owning the present, and future: cholinergic modulation decreases semantic perseverations in a person with post-stroke aphasia

    Aphasiology
    2022-11-02 | Journal article
    DOI: 10.1080/02687038.2021.1957082
    CONTRIBUTORS: Marcelo L. Berthier; Daniel Santana-Moreno; Álvaro Beltrán-Corbellini; Juan C. Criado-Álamo; Lisa Edelkraut; Diana López-Barroso; Guadalupe Dávila; María José Torres-Prioris